Global X Cloud Computing ETF vs Charles River Laboratories Intl. Inc — how do they compare? Global X Cloud Computing ETF trades at $27.79, while Charles River Laboratories Intl. Inc trades at $281.43 (market cap $13.46B). Which is the better fit depends on your goals.
| CLOU | CRL | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $28.09 | $282.00 |
52-Week Low | $17.60 | $145.57 |
Market Cap | — | $13.46B |
Enterprise Value | — | $16.30B |
Signals from Pluang's Aura AI — not financial advice
CLOU, the Global X Cloud Computing ETF, trades at $27.66, down 1.53% on the day, with a bullish technical signal from moving averages and ADX indicators. The ETF provides diversified exposure to cloud computing stocks, with recent news highlighting long-term growth potential beyond AI hype, driven by strong holdings like Snowflake and Datadog. RSI levels above 80 indicate overbought conditions, suggesting near-term caution.
The outlook for CLOU remains positive due to structural growth in cloud adoption, though high RSI readings and competition from other cloud ETFs pose risks. Investor sentiment is buoyed by resilient subscription revenues and diversification benefits, but volatility in tech stocks and macroeconomic pressures could impact performance.
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →